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Iatrogenic hypoglycemia is the limiting factor in the glycemic management of diabetes.1 It causes recurrent illness in most people with type 1 diabetes mellitus and in many with advanced type 2 diabetes mellitus and is 
sometimes fatal. It generally precludes maintenance of euglycemia over a lifetime of 
diabetes and thus full realization of the benefits of glycemic control. Various mecha-
nisms, discussed in this review, cause a vicious cycle of recurrent hypoglycemia.
Compromised Defenses ag a ins t H y po glycemi a
As plasma glucose levels fall, the physiologic defenses against hypoglycemia1,2 are 
a decrease in the secretion of the glucose-lowering pancreatic beta-cell hormone 
insulin, an increase in the secretion of the glucose-raising pancreatic alpha-cell 
hormone glucagon, and in the absence of an increase in glucagon, an increase in 
the secretion of the glucose-raising adrenomedullary hormone epinephrine. The 
normal behavioral defense is carbohydrate ingestion, prompted by neurogenic 
(autonomic) symptoms that largely originate from a sympathetic neural response.1 
These defenses are illustrated in Figure 1. Their effectiveness ensures a continuous 
supply of glucose to the brain.1
In people with diabetes, therapeutic insulin excess caused by treatment with 
insulin, sulfonylureas, or glinides can initiate a hypoglycemic episode. Marked 
absolute therapeutic insulin excess can occasionally cause hypoglycemia in pa-
tients with intact defenses against hypoglycemia1 (Fig. 2). Typically, however, 
hypoglycemia occurs during less marked or even relative therapeutic insulin ex-
cess (insulin levels insufficient to cause hypoglycemia under most conditions but 
high enough to cause it in the context of decreased exogenous glucose delivery 
or endogenous glucose production, increased glucose use, or increased sensitiv-
ity to insulin1) in patients with compromised defenses against hypoglycemia. 
Such patients — those with established type 1 diabetes or advanced type 2 dia-
betes1 — have beta-cell failure or absolute endogenous insulin deficiency (Fig. 2). 
As plasma glucose levels fall, the compromised physiologic defenses include fail-
ure of insulin levels to diminish (in the absence of endogenous insulin secretion, 
circulating insulin levels are a function of the absorption and clearance of in-
jected insulin, not insulin secretion), failure of glucagon secretion to increase,1,5,6 
and attenuated epinephrine secretion1,7-9 (Fig. 2). This combination of compro-
mised physiologic defenses causes the clinical syndrome of defective glucose 
counterregulation, which increases the risk of recurrent severe hypoglycemia by 
a factor of 25 or more.1
The compromised behavioral defense, as plasma glucose levels fall, is the fail-
ure to ingest carbohydrates because of the absence of symptoms of hypoglycemia; 
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their absence reflects the attenuation of the sym-
pathoadrenal response (largely the sympathetic 
neural response)1 (Fig. 2). That attenuation causes 
the clinical syndrome of hypoglycemia unaware-
ness (or impaired awareness of hypoglycemia), 
which increases the risk of recurrent severe hy-
poglycemia by a factor of 6 or more.1
A pivotal finding is that hypoglycemia attenu-
ates defenses (including increased epinephrine 
secretion and symptomatic defenses) against 
subsequent hypoglycemia in nondiabetic per-
sons10 and patients with type 1 diabetes.7 That 
led to the concept of hypoglycemia-associated 
autonomic failure (HAAF) in diabetes (Fig. 2). 
According to this concept, recent hypoglycemia 
(or sleep or prior exercise) causes both defective 
glucose counterregulation (by attenuating the 
adrenomedullary epinephrine response, in the 
context of an insulin concentration that is not 
reduced and glucagon secretion that is not in-
creased) and hypoglycemia unawareness (largely 
by attenuating the sympathetic neural response) 
and thus a vicious cycle of recurrent hypoglyce-
mia.1,7,8 With regard to the pathophysiological 
mechanisms of HAAF, one needs to explain not 
only the lack of a decrease in insulin and of an 
increase in glucagon but also the attenuated 
sympathoadrenal — adrenomedullary and sym-
pathetic neural — responses to declining glu-
cose concentrations.
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Figure 1. Physiologic and Behavioral Defenses against Hypoglycemia in Humans.
Physiologic defenses against falling glucose concentrations include a decrease in insulin secretion, an increase in glucagon secretion, 
and an increase in epinephrine secretion. Behavioral defenses include carbohydrate ingestion prompted by neurogenic symptoms. All 
these are compromised in patients with absolute endogenous insulin deficiency. Adapted from Cryer.3
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Loss of Insulin and Glucagon Responses
The mechanism underlying the failure of circu-
lating insulin levels to fall as glucose levels fall in 
patients with type 1 diabetes or advanced type 2 
diabetes is straightforward. In the absence of en-
dogenous insulin secretion (beta-cell failure), cir-
culating insulin levels are simply a function of 
the absorption and clearance of injected insulin.1
The mechanism of the lack of an increase in 
glucagon is different from that of the attenua-
tion of the sympathoadrenal responses.1 Loss of 
the glucagon response precedes attenuation of 
the epinephrine response,1,6,11 is independent of 
diabetic autonomic neuropathy,1,7 and is not cor-
rected by scrupulous avoidance of hypoglyce-
mia.1,12
The lack of an increase in alpha-cell glucagon 
secretion is also best attributed to beta-cell fail-
ure — specifically, the lack of a decrease in the 
alpha-cell inhibitory signal of beta-cell insu-
lin1,13 (Fig. 3). The evidence for this conclusion 
has been reviewed previously13 and is summa-
rized here. First, loss of the insulin response and 
loss of the glucagon response are correlat-
ed,6,11,14,15 and they develop early in the course 
of type 1 diabetes6,11 but late in the course of 
type 2 diabetes.8 Second, the glucagon response 
to hypoglycemia is not critically dependent on 
innervation. Normal glucagon secretion in re-
sponse to hypoglycemia occurs in humans with 
a transplanted (denervated) pancreas,16 as well 
as in humans with spinal cord transections17
(and, thus, no sympathoadrenal outflow from 
the brain to the islets) and dogs with a dener-
vated pancreas18; glucagon secretion is also 
normal in the perfused rodent pancreas and 
perfused rodent and human islets. Thus, loss of 
the glucagon response cannot be attributed to 
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Figure 2. Schematic Diagram of Hypoglycemia-Associated Autonomic Failure (HAAF) in Diabetes.
Although marked insulin excess can cause occasional episodes of hypoglycemia in patients with relative beta-cell 
failure, less marked insulin excess often causes hypoglycemia in patients with hypoglycemia-associated autonomic 
failure (defective glucose counterregulation and hypoglycemia unawareness). Adapted from Cryer.4
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islet denervation, and the causative abnormality 
in type 1 diabetes and advanced type 2 diabetes 
must reside within the islets.
Third, because there is a glucagon response 
to administered amino acids in patients with 
type 1 diabetes,5,19,20 loss of the glucagon re-
sponse to hypoglycemia must be the result of 
reduced signaling of functional alpha cells to 
secrete glucagon during hypoglycemia. Fourth, 
because insulin normally regulates glucagon 
secretion in a reciprocal fashion in humans20-25
and laboratory animals, it follows that loss of 
beta-cell insulin secretion would result in loss of 
the signal of a decrease in insulin to increase 
alpha-cell glucagon secretion, despite a low glu-
cose level in the alpha cells (Fig. 3). This mecha-
nism for loss of the glucagon response to hypo-
glycemia does not exclude the possibility of 
additional intra-islet mechanisms, such as exces-
sive delta-cell secretion of somatostatin.26
These data support the conclusion that in 
diabetes characterized by an absolute deficiency 
of endogenous insulin secretion — type 1 diabe-
tes and advanced type 2 diabetes — the lack of 
a decrease in beta-cell insulin secretion causes 
the loss of an increase in alpha-cell glucagon 
secretion as glucose concentrations fall in re-
sponse to therapeutic hyperinsulinemia.1 The 
lack of a decrease in insulin and the lack of an 
increase in glucagon are prerequisites for defec-
tive glucose counterregulation but do not cause 
defective glucose counterregulation or hypogly-
cemia unawareness. Those two components of 
HAAF in diabetes develop only when the sympa-
thoadrenal and symptomatic responses to hypo-
glycemia become attenuated1 (Fig. 2).
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Figure 3. Mechanisms of Loss of the Glucagon Response.
Panel A shows the physiological effect of a decrease in insulin coupled with a low glucose concentration in stimulat-
ing alpha-cell glucagon secretion, and Panel B shows the pathophysiological effect of beta-cell failure and the result-
ing loss of a decrease in insulin secretion and loss of an increase in alpha-cell glucagon secretion, despite a low glu-
cose concentration. Adapted from Cryer.13
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Attenuation of Sympathoadrenal Responses
Attenuated sympathoadrenal responses to hypo-
glycemia are commonly caused by recent hypo-
glycemia1,7,8,10 but can also be caused by sleep27,28 
or prior exercise.29 Unlike the loss of the insulin 
and glucagon responses at the islet level, the al-
teration resulting in attenuated sympathoadre-
nal responses must reside within the central 
nervous system (CNS) or its afferent or efferent 
connections.
One limitation of research on the mechanism 
underlying attenuated sympathoadrenal respons-
es in humans has been the need for noninvasive 
methods of measuring human brain function. 
As discussed below, new techniques of positron-
emission tomography (PET), magnetic resonance 
imaging, and magnetic resonance spectroscopy 
are now addressing that need. Other limitations 
are the failure of many studies to document 
which patients with diabetes have HAAF (i.e., 
documented attenuation of the plasma epineph-
rine and neurogenic symptom responses to 
controlled hypoglycemia) and which patients do 
not and the failure to study the putative mecha-
nisms of HAAF in both patient groups and non-
diabetic controls. A more efficient approach is to 
study a putative mechanism of HAAF in nondia-
betic persons both before a period of hypoglyce-
mia, when normal plasma epinephrine and 
neurogenic symptom responses to controlled 
hypoglycemia can be documented, and after a 
period of hypoglycemia, when attenuated re-
sponses can be documented.10,30,31 Incidentally, 
the findings that attenuated sympathoadrenal 
and symptomatic responses to hypoglycemia can 
be induced by recent hypoglycemia in nondia-
betic persons10,30,31 and can be reversed by scru-
pulous avoidance of hypoglycemia in patients 
with diabetes1,12 underscore the fact that these 
key features of HAAF are functional rather than 
structural (i.e., neuropathic) in origin.1
Hypotheses regarding CNS-mediated mech-
anisms of the attenuated sympathoadrenal re-
sponses to hypoglycemia that cause HAAF in-
clude the systemic-mediator hypothesis, the brain 
fuel–transport hypothesis, the brain-metabo-
lism hypothesis, and the cerebral-network hy-
pothesis.1,32,33
Systemic-Mediator Hypothesis
This hypothesis holds that increased circulating 
cortisol levels or perhaps some other factor dur-
ing recent hypoglycemia acts on the brain to at-
tenuate the sympathoadrenal and symptomatic 
responses to subsequent hypoglycemia.34,35 How-
ever, neither prior cortisol elevations similar to 
those that occur during hypoglycemia36,37 nor 
inhibition of the cortisol response to prior hypo-
glycemia with metyrapone37 prevents the attenu-
ated epinephrine and symptomatic responses to 
subsequent hypoglycemia in humans.
Brain Fuel–Transport Hypothesis
According to this hypothesis, recent hypoglyce-
mia causes increased blood-to-brain transport of 
glucose (or of an alternative metabolic fuel) and 
thus attenuates sympathoadrenal and symptom-
atic responses to subsequent hypoglycemia.1 
This hypothesis was initially based on the find-
ing that hypoglycemia persisting for 3 days38 or 
longer39 results in increased expression of glu-
cose transporter 1 (GLUT-1) in the cerebral vas-
culature and in increased brain glucose uptake in 
rats. However, hypoglycemia for just 2 hours re-
sults in attenuated sympathoadrenal and symp-
tomatic responses to subsequent hypoglycemia 
in humans.10 In addition, brain glucose uptake 
(calculated from arteriovenous glucose differ-
ences across the brain and estimates of cerebral 
blood flow [the Kety–Schmidt technique]) was 
reported to be maintained during a subsequent 
episode of hypoglycemia in nondiabetic persons 
with a prior episode40 and in patients with type 1 
diabetes who had relatively low glycated hemo-
globin levels and thus probably more recent hy-
poglycemia.41 In both instances, however, the 
difference in calculated brain glucose uptake was 
due to greater estimated cerebral blood flow 
rather than increased arteriovenous glucose dif-
ferences across the brain.
The glucose-transport hypothesis was not sup-
ported by PET measurements. Global blood-to-
brain glucose transport, measured with [1-11C]
glucose PET, was not reduced in patients with 
poorly controlled type 1 diabetes42 and was not 
increased after nearly 24 hours of interprandial 
hypoglycemia,30 which produces a model of 
HAAF (including attenuated epinephrine and 
neurogenic symptom responses to hypoglyce-
mia) in nondiabetic persons.30,31 Furthermore, 
global blood-to-brain [11C]3-O-methylglucose 
transport43 and [18F]deoxyglucose transport,44 
both measured with PET, were not increased in 
patients with type 1 diabetes who were thought 
to have hypoglycemia unawareness.
The brain fuel–transport hypothesis may be 
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flawed. The premise is that hypoglycemia causes 
a decrease in the rate of cerebral glucose metabo-
lism, which in turn causes an increase in sym-
pathoadrenal activity, and that prior hypoglyce-
mia may somehow increase the cerebral transport 
of glucose to the brain, minimizing the decrease 
in the rate of cerebral glucose metabolism and 
thus attenuating the increase in sympathoadre-
nal activity. However, there is no evidence that a 
decrease in the rate of cerebral glucose metabo-
lism causes an increase in sympathoadrenal ac-
tivity (that response could be a signaling event), 
and it is unclear how low the plasma glucose 
concentration has to be to limit oxidative brain 
metabolism, but it may be quite low. The rate of 
blood-to-brain glucose transport exceeds the rate 
of cerebral glucose metabolism even at plasma 
glucose concentrations of 65 mg per deciliter 
(3.6 mmol per liter) in humans.30,42
Extrapolation of the linear relationship be-
tween plasma and brain glucose concentrations, 
the latter measured with 13C magnetic resonance 
spectroscopy, in nondiabetic persons and patients 
with type 1 diabetes during euglycemia and hy-
poglycemia, as reported by van de Ven and col-
leagues,45 suggests that the plasma glucose 
concentration at which the brain glucose con-
centration would become zero — at which point 
brain glucose metabolism would have to decrease 
— is less than 36 mg per deciliter (2.0 mmol per 
liter). An increase in blood-to-brain glucose 
transport would not increase brain glucose me-
tabolism unless it shifted from below to above 
that unknown, but seemingly low, glycemic 
threshold.
There was no significant difference in brain 
glucose concentrations between the nondiabetic 
persons and the patients with type 1 diabetes in 
the study by van de Ven and colleagues,45 sug-
gesting no difference in blood-to-brain glucose 
transport. Assuming the patients with type 1 
diabetes did not have HAAF (epinephrine re-
sponses in these patients were similar to those 
in nondiabetic persons, and symptoms of hypo-
glycemia were not reported), commentators sug-
gested that blood-to-brain glucose uptake might 
have been increased in patients with HAAF, if 
they had been included in the study.46 That in-
ference was made on the basis of two observa-
tions: a 15% higher occipital–cortical brain 
glucose concentration in patients with type 1 
diabetes than in nondiabetic persons, as mea-
sured with 1H magnetic resonance spectroscopy 
under nonphysiologic conditions (infusions of 
somatostatin, insulin, and 50% glucose) with 
hyperglycemia (approximately 300 mg per deci-
liter [16.7 mmol per liter]),47 and no significant 
difference in cortical brain glucose metabolism, 
as measured with 13C magnetic resonance spec-
troscopy under similar nonphysiologic condi-
tions with hyperglycemia, between patients with 
type 1 diabetes and nondiabetic persons.48 Al-
though the patients with type 1 diabetes were 
assumed to have HAAF, they were not shown to 
have attenuated epinephrine and symptomatic 
responses to hypoglycemia.
Notably, the same investigative group found 
no effect of recurrent episodes of hypoglycemia, 
which produced a model of HAAF (attenuated 
epinephrine and neurogenic symptom responses 
to hypoglycemia), on brain glucose concentra-
tions measured with 1H magnetic resonance 
spectroscopy under similar nonphysiologic condi-
tions with hyperglycemia.49 Because the brain 
glucose concentration is a direct function of the 
plasma glucose concentration,45 the unaltered 
brain glucose concentration does not support the 
conclusion that increased blood-to-brain glucose 
transport might be the mechanism of HAAF.46
If the normally small astrocytic brain glyco-
gen pool1 increases substantially (reflecting gly-
cogen supercompensation) after hypoglycemia, 
that expanded source of glucose within the brain 
could result in an attenuated sympathoadrenal 
response during subsequent hypoglycemia.50 
However, the evidence in rats that brain glyco-
gen content increases substantially after hypo-
glycemia has not been confirmed,51 and the 
glycogen-supercompensation hypothesis has not 
been supported in humans.52 Brain glycogen 
was not increased in patients with type 1 diabe-
tes who were selected for hypoglycemia un-
awareness. Because brain glycogen synthesis is a 
direct function of the plasma glucose concentra-
tion and blood-to-brain glucose transport, in-
creased blood-to-brain glucose transport should 
result in increased brain glycogen. That was not 
the case in the patients selected for hypoglyce-
mia unawareness.52
Neurons oxidize lactate,53 but that lactate is 
largely derived from glucose within the brain.1 
An increase in blood-to-brain lactate transport is 
a plausible mechanism of HAAF, although, as dis-
cussed above regarding glucose, this idea as-
sumes that a decrease in brain oxidative metabo-
lism causes an increase in sympathoadrenal 
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activity and, if so, lactate metabolism would 
have to be sufficient to raise brain oxidative 
metabolism. Lactate infusions resulting in in-
creases in circulating lactate levels by a factor of 
approximately 4 in nondiabetic persons54 and by 
approximately 2 in nondiabetic persons and pa-
tients with type 1 diabetes55,56 reduced epineph-
rine responses to, and symptoms of, hypoglyce-
mia in both the nondiabetic persons and the 
patients with type 1 diabetes. Plasma lactate 
concentrations roughly double during hyperin-
sulinemia.20 Arteriovenous measurements have 
revealed lactate release from the brain in the 
euglycemic state and either no lactate uptake57 
or a small amount of lactate uptake, sufficient to 
compensate for only about 25% of the calculated 
brain glucose energy deficit58 during hyperinsu-
linemic hypoglycemia in humans.
Studies of systemic lactate infusions with 13C 
magnetic resonance spectroscopic measurements 
in nondiabetic persons have shown brain lactate 
uptake when arterial lactate levels are increased 
by a factor of 4 and increased lactate transport 
to the brain when plasma lactate levels are in-
creased by a factor of 2.59,60 Indeed, increased 
brain lactate concentrations without increased 
oxidation of lactate have been reported in pa-
tients with type 1 diabetes.61 Lactate infusions 
that caused only a small increase in brain lactate 
metabolism were found to result in maintenance 
of brain glucose metabolism during subsequent 
hypoglycemia in rats subjected to recurrent hy-
poglycemia.62
Brain-Metabolism Hypothesis
This hypothesis holds that recent hypoglycemia 
alters CNS metabolic regulation, resulting in at-
tenuated sympathoadrenal responses to declining 
plasma glucose concentrations and thus HAAF. 
Studies of the cellular and molecular biology and 
pathophysiology of CNS control of glucose coun-
terregulation in rodent models have focused 
largely, but not exclusively, on the ventromedial 
hypothalamus. Potential mechanisms32,33,63-65 in-
clude decreased glucose sensing by glucose-excited 
or glucose-inhibited neurons in the hypothala-
mus, elsewhere in the brain, and in the periphery; 
decreased activation of AMP kinase; increased 
glucokinase activity; loss of a decrease in the 
counterregulatory inhibitor γ-aminobutyric acid; 
loss of an increase in the counterregulatory stim-
ulator glutamine; increased urocortin release; 
and reduced actions of insulin on the brain.
One or more of these basic clues from a 
 variety of studies may ultimately lead to clinical 
strategies that prevent hypoglycemia. Pending 
that, there are clues from studies in humans that 
may lead to strategies that lower the barrier of 
hypoglycemia in diabetes66 (Fig. 4).
Several agents, such as glucagon, glucagon-
stimulating amino acids, β2-adrenergic agonists 
(e.g. terbutaline), and adenosine antagonists (e.g., 
caffeine), are known to raise glucose concentra-
tions. Their therapeutic potential is limited be-
cause their glucose-raising actions are not in-
creased in response to falling glucose levels.66 
Nonetheless, the judicious use of such agents 
could prove beneficial if their efficacy and safety 
were demonstrated in randomized clinical trials.
Five potential treatments for reversing glu-
cose counterregulatory defects66 — selective 
serotonin-reuptake inhibitors (SSRIs),67,68 adren-
ergic antagonists,69 an opiate-receptor antago-
nist,70,71 fructose,72 and a selective ATP-sensitive 
potassium (KATP)–channel agonist73 — are of 
particular interest. All enhance counterregulatory 
responses to falling glucose concentrations.66
SSRIs increase the counterregulatory respons-
es to hypoglycemia in humans67 and rats.68 A 
randomized clinical trial of an SSRI for the pre-
vention of iatrogenic hypoglycemia may be war-
ranted. Combined α-adrenergic and β-adrenergic 
blockade prevents the attenuation of sympatho-
adrenal responses the day after hypoglycemia in 
humans.69 If that were shown to be predomi-
nantly an effect of β1-adrenergic blockade, a 
trial of a β1-adrenergic antagonist for the pre-
vention of hypoglycemia in patients with type 1 
diabetes would be reasonable and might reduce 
mortality.74 β1-adrenergic blockade would not 
impair the β2-adrenergic actions of catecho-
lamines, such as their glucose-raising and symp-
tom-generating effects. Infusion of the opioid-
receptor antagonist naloxone increases the plasma 
epinephrine response to hypoglycemia and, when 
administered during hypoglycemia, prevents at-
tenuation of the plasma epinephrine response to 
subsequent hypoglycemia in humans.70,71 Fructose 
infusion amplifies epinephrine and glucagon 
responses and increases glucose production dur-
ing hypoglycemia in humans.72 Finally, adminis-
tration of a selective Kir6.2/SUR-1 KATP-channel 
agonist increases the epinephrine response to 
hypoglycemia in rats.73 However, systemic ad-
ministration of the nonselective KATP-channel 
agonist diazoxide suppresses the glucagon re-
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sponse and has no effect on the epinephrine re-
sponse to hypoglycemia in nondiabetic humans.22
Cerebral-Network Hypothesis
According to this hypothesis, recent hypoglyce-
mia acts through a network of interconnected 
brain regions to inhibit hypothalamic activation 
and thus attenuate the sympathoadrenal and 
symptomatic responses to subsequent hypogly-
cemia.1,31 The cerebral-network hypothesis is 
largely based on findings from functional neuro-
imaging in humans during hypoglycemia,43,44 
particularly [15O]water PET measurements of re-
gional cerebral blood flow as an index of region-
al brain synaptic activity,31,75,76 and the psycho-
physiological concept of habituation of the 
response to a given stress and its proposed 
mechanism.77 The posterior paraventricular nu-
cleus of the thalamus is a brain site at which 
previous stress, such as stress induced by re-
straint, acts to attenuate responses to subsequent 
episodes of that stress in rats.78 Lesions in the 
posterior paraventricular nucleus of the thalamus 
block habituation of the hypothalamic–pituitary–
adrenocortical response to repeated restraint.78 
Habituation of the sympathoadrenal response to 
repeated restraint-induced stress has also been 
documented in rats.79
Recent hypoglycemia attenuates sympathoad-
renal responses to subsequent hypoglycemia in 
nondiabetic persons10 and in patients with dia-
betes,7 an example of habituation of the sympa-
thoadrenal response to hypoglycemia in humans. 
Hypoglycemia has been found to increase synap-
tic activity in the human dorsal midline thala-
mus, among other brain sites,31,75,76 and to in-
crease synaptic activity to a greater extent after 
recent hypoglycemia only in the dorsal midline 
thalamus (Fig. 5),31 the site of the posterior 
paraventricular nucleus of the thalamus.78 In-
deed, slightly subphysiologic glucose concentra-
tions (65 mg per deciliter) increase synaptic 
activity in the dorsal midline thalamus pre-
dominantly, perhaps selectively, in humans.80 
Thus, thalamic synaptic activation may be in-
volved in the pathogenesis of the attenuated 
sympathoadrenal and symptomatic responses to 
hypoglycemia that are the key features of HAAF 
in diabetes.31,80
Inactivation of the medial prefrontal cortex 
has also been reported to prevent habituation 
to restraint-induced stress in rats.81 Increased 
synaptic activity in the medial prefrontal cortex 
(anterior cingulate) occurs during hypoglyce-
mia in humans.31,75,76 Thus, the medial pre-
frontal cortex, among other regions, may be 
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Figure 4. Elimination of Hypoglycemia from the Lives of People with Diabetes.
Prevention or cure of diabetes or provision of plasma-glucose–regulated insulin replacement or secretion would 
eliminate hypoglycemia. In the meantime, available drugs might reduce the burden of iatrogenic hypoglycemia. 
GABA denotes γ-aminobutyric acid, and KATP ATP-sensitive potassium. Adapted from Cryer.66
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part of the cerebral network involved in the 
 attenuated sympathoadrenal and symptomatic 
responses to hypoglycemia that characterize 
HAAF in diabetes.
A greater decrease in [18F]deoxyglucose up-
take, measured with the use of PET, in the sub-
thalamic region of the brain, centered on the 
hypothalamus, during hypoglycemia has been 
reported in patients with type 1 diabetes and 
hypoglycemia unawareness, as compared with 
those without hypoglycemia unawareness.44 In-
deed, the array of differences in the patterns of 
[18F]deoxyglucose uptake during hypoglycemia 
between patients with hypoglycemia unaware-
ness and those without it44 is consistent with the 
participation of a widespread cerebral network 
in the pathogenesis of HAAF in diabetes.
Summ a r y
The key feature of HAAF in diabetes is attenuat-
ed sympathoadrenal responses to hypoglycemia, 
most often caused by recent hypoglycemia. In the 
context of the lack of a decrease in insulin and of 
an increase in glucagon — both plausibly attrib-
uted to beta-cell failure — attenuation of the epi-
nephrine response causes defective glucose coun-
terregulation. Attenuation of the sympathetic 
neural response largely causes hypoglycemia un-
awareness. The precise mechanisms of the attenu-
ated sympathoadrenal responses are not known, 
but there are provocative clues, ranging from evi-
dence that available drugs might lower the bur-
den of iatrogenic hypoglycemia and that lactate 
can affect brain metabolism to the notion of al-
terations in a cerebral network in the pathogen-
esis of HAAF.
Disclosure forms provided by the author are available with the 
full text of this article at NEJM.org.
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Figure 5. Increased Thalamic Response to Hypoglycemia in a Model of HAAF.
A model of HAAF in humans shows a greater increase in dorsal midline 
thalamus activation, as measured with the use of [15O]water positron-emission 
tomography, during hypoglycemia on day 2 than during hypoglycemia on 
day 1, with interprandial hypoglycemia occurring between the measure-
ments on day 1 and day 2. Areas with the greatest activity are yellow, and 
those with the least activity are dark red. Adapted from Arbeláez et al.31
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